menu
    • menu
    [{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"RNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Serina Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serina Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Serina Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Merger","leadProduct":"POZ-Apomorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Serina Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Serina Therapeutics \/ Serina Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Serina Therapeutics \/ Serina Therapeutics"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"Serina Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enable Injections and Serina to Develop SER-252 for Advanced Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"POZ-Apomorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Serina Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serina Therapeutics \/ Serina Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Serina Therapeutics \/ Serina Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Serina Therapeutics

    Menu

    Serina Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Serina Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Serina Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : POZ-Apomorphine

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Recipient : Enable Injections

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Enable Injections and Serina to Develop SER-252 for Advanced Parkinson's Disease

                            Details : The combined company will focus on advancing IND-enabling studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.

                            Brand Name : SER-252

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 15, 2024

                            Lead Product(s) : POZ-Apomorphine

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Recipient : Enable Injections

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Serina Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Serina Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : POZ-Apomorphine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : AgeX Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

                            Details : The combined company will focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.

                            Brand Name : SER-252

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 26, 2024

                            Lead Product(s) : POZ-Apomorphine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : AgeX Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Serina Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Serina Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Therapeutic

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

                            Details : The agreement provides access to Serina's POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations for RNA-based therapeutics.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 17, 2023

                            Lead Product(s) : RNA-based Therapeutic

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth